<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Only a small proportion of children who might benefit from bone marrow transplant (BMT) have an HLA-identical sibling </plain></SENT>
<SENT sid="1" pm="."><plain>To provide this potentially curative therapy to patients without a matched related donor, marrow transplants using less well matched related donors or unrelated donors (identified through computerized donor registries) have been performed </plain></SENT>
<SENT sid="2" pm="."><plain>We report the outcome of 24 consecutive unrelated donor BMT's performed on children </plain></SENT>
<SENT sid="3" pm="."><plain>Eligible diagnosis included <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> (AL) (n = 15), <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) (n = 4), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (n = 3), and severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) (n = 2) </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> donor/recipient pairs were sero-matched at 5 or 6 of the 6 HLA A, B, and DR antigens </plain></SENT>
<SENT sid="5" pm="."><plain>Several different preparative regimens were used, but fractionated total body irradiation (TBI) was used in 20 patients </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> recipients received <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host-disease</z:e> (GVHD) prophylaxis with <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>-A (CSA), four with short course <z:chebi fb="0" ids="44185">methotrexate</z:chebi> (MTX), 14 in combination with short course MTX and <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> (MPS), and five in combination with a mouse monoclonal antibody to CD5, coupled to the A-chain of ricin (Xomazyme-65) </plain></SENT>
<SENT sid="7" pm="."><plain>One patient received CSA and MPS alone after a T-cell depleted marrow transplant </plain></SENT>
<SENT sid="8" pm="."><plain>Twenty of 23 evaluable recipients engrafted (87%) </plain></SENT>
<SENT sid="9" pm="."><plain>Two patients with <z:mp ids='MP_0005481'>CML</z:mp> never engrafted and had autologous marrow recovery, one patient with SAA died at 128 days without evidence of engraftment, and there was one early <z:hpo ids='HP_0011420'>death</z:hpo> at day + 9 </plain></SENT>
<SENT sid="10" pm="."><plain>Fourteen of 20 patients (70%) with stable donor-derived hematopoiesis developed significant <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD &gt; or = grade II) </plain></SENT>
<SENT sid="11" pm="."><plain>Eleven of 15 engrafted patients who survived &gt; 100 days after BMT developed <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD (73%).(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>